This website is intended for healthcare professionals only.
EXTENDING THE CONTINUUM OF CARE IN 3L mCRC:
FROM SCIENTIFIC EVIDENCE TO DAILY CLINICAL PRACTICE
Prof. Chiara Cremolini MD, PhD
Responsible for the scientific activities of Santa Chiara Hospital’s oncology unit in Trento, Italy, President of the GONO and active member of ESMO GI.
Dr. Anelisa K. Coutinho MD Clinical oncologist and coordinator of the gastrointestinal tumors department at Clínica AMO in Salvador, Brazil. Founding director of the GTG. Active member of the SBOC, ASCO, ESMO, and the scientific committee of ESMO GI.
This webinar focuses on 3L treatments in metastatic colorectal cancer (mCRC) to extend the continuum of care, as well as the impact of pronostic factors on OS and PFS. FTD/TPI and regorafenib, the current approved 3L options in Europe and Latin America, add treatment lines and increase overall survival. FTD/TPI, in particular, has a manageable toxicity profile and extends patients' continuum of care. An interactive clinical patient case is presented throughout the webinar to underline the contribution of FTD/TPI as 3L treatment.
Key points covered
This webinar presented current 3L options in mCRC to extend the continuum of care.
An interactive clinical patient case was presented, with a focus on the choice of the 3L treatment.
This webinar showed that prognostic factors impact the OS and PFS of pre-treated patients.
This webinar highlighted the value of FTD/TPI as a 3L therapy option in extending patients’ continuum of care.
Webinar Replay
Featured Speakers
Prof. Chiara Cremolini
Prof Chiara Cremolini is an Associate Professor in Medical Oncology at the University of Pisa, Italy. She is responsible for the scientific activities of the Clinical Trials Office of Santa Chiara Hospital's Oncology Unit. She is also the president of the GONO and an active member of ESMO GI.
Dr. Anelisa K. Coutinho
Dr Anelisa K. Coutinho is a clinical oncologist and coordinator of the Gastrointestinal Tumors department at Clínica AMO in Salvador, Brazil. She is the founding director of the GTG, an active member of the SBOC, ASCO, and ESMO, as well as a member of the Scientific Committee of ESMO GI.
